Policy | July 11, 2025
EU launches strategies to strengthen crisis readiness and health security
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
25 women students to receive internship, training, and mentorship in Life Sciences segment
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Findings likely to generate hypotheses about potential new uses of drugs
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Subscribe To Our Newsletter & Stay Updated
